胃癌是第五大最常诊断的恶性肿瘤，也是癌症相关死亡的第三大原因。然而，传统的手术和化疗干预措施在临床实践中的治疗效果往往并不令人满意。姜黄素 (Cur) 在先前的研究中已显示出作为治疗剂的前景。然而，其在这方面的进展受到了溶解度低、水环境不稳定和快速代谢等挑战的阻碍。在本研究中，我们通过微流控电喷雾技术开发了甲基丙烯酸鱼明胶（FGMA）水凝胶微粒（FGMPs@Cur）封装Cur，用于胃癌术后综合治疗。进行了全面的表征和分析，以评估 FGMPs@Cur 对胃癌细胞的细胞毒性和潜在的组织修复作用。体外实验表明，在细胞相容性测试中，FGMPs@Cur对近80%的胃癌细胞表现出显着的细胞毒作用，同时保持至少95%的正常细胞活力。体内结果表明，FGMPs@Cur 显着地将肿瘤体积缩小至对照组的 47%，并且在手术部位观察到显着的组织再生。这些特性表明，这种水凝胶微粒系统在实际应用中是胃癌术后治疗的有希望的候选者。版权所有 © 2023。由 Elsevier B.V. 出版。

Gastric cancer is the fifth most frequently diagnosed malignant neoplasm and the third leading cause of cancer-related mortality. Nevertheless, the therapeutic efficacy of conventional surgical and chemotherapeutic interventions in clinical practice is often unsatisfactory. Curcumin (Cur) has shown promise as a therapeutic agent in prior studies. However, its progress in this context has been impeded by challenges including low solubility, instability in aqueous environments, and rapid metabolism. In this study, we develop methacrylate fish gelatin (FGMA) hydrogel microparticles (FGMPs@Cur) encapsulating Cur via microfluidic electrospray technology for postoperative comprehensive treatment of gastric cancer. Comprehensive characterizations and analyses were conducted to assess the cytotoxicity against gastric cancer cells and potential tissue reparative effects of FGMPs@Cur. In vitro experiments revealed that FGMPs@Cur exhibited a remarkable cytotoxic effect on nearly 80 % of gastric cancer cells while maintaining at least 95 % viability of normal cells in cell compatibility tests. In vivo results demonstrated that FGMPs@Cur significantly reduced tumor volume to 47 % of the control group, and notable tissue regeneration was observed at the surgical site. These properties indicated that such a hydrogel microparticle system is a promising candidate for postoperative gastric cancer treatment in practical application.Copyright © 2023. Published by Elsevier B.V.